What happened with ELMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Electromed makes the prescription-only SmartVest system for people who have difficulty clearing mucus from their lungs. The system uses a vest and air-pressure pulses to create rapid chest-wall oscillations that help clear the airways. Patients include people with bronchiectasis, cystic fibrosis and certain neuromuscular disorders.
Most revenue comes from U.S. homecare. Clinicians refer patients to Electromed, which handles insurance claims, delivers the system and teaches patients to use it at home. This direct sales model bypasses traditional home medical equipment distributors. Commercial insurers and Medicare supply most homecare revenue, with patients responsible for costs their coverage does not pay. Hospital sales and sales through distributors are much smaller parts of the business.
The business depends on clinician referrals and insurance coverage, not just demand for the device. SmartVest requires a prescription, and Medicare reimbursement is limited to qualifying conditions and evidence that a less expensive treatment did not adequately clear retained secretions. Payments can fall below allowed reimbursement amounts because of deductibles, copayments and coverage limits; installment payments can also stop if coverage changes or patients discontinue use.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Electromed’s results hinge on clinician referrals and insurance reimbursement for home airway clearance; Baxter and Philips are also key direct competitors missing from this list.
Tactile Systems Technology, Inc., operating as Tactile Medical, competes with Electromed’s SmartVest for home airway-clearance patients through AffloVest, which it sells to home medical equipment providers that handle reimbursement paperwork, patient training and support. Watch AffloVest revenue rather than Tactile’s overall results: the competing product accounted for only 16% of its revenue in 2025.
Tactile Systems Technology, Inc. earningsTCMD
Tactile Medical’s AffloVest revenue will show whether its push through home medical equipment providers is intensifying competition with Electromed’s SmartVest for airway-clearance patients.
Focus on AffloVest revenue, not Tactile’s overall results: AffloVest accounted for only 16% of Tactile’s 2025 revenue. Growth would show the competing product gaining ground through home medical equipment providers, potentially making it harder for Electromed to win the same patients and clinician referrals. Weakness would point to less pressure from this route, but would not establish how Electromed’s own sales are doing.
Electromed, Inc. earningsThis company
Electromed’s report will show whether clinician referrals and payer reimbursement are still growing SmartVest homecare revenue while preserving its product margin.
Read homecare revenue growth alongside gross margin. Growth with a steady margin would mean Electromed is converting more referrals into approved systems without giving up much profit per system. Slower growth or a falling margin would make approval volume, net revenue per approval and the cost of serving patients important clues to whether growth is becoming harder to turn into profit.
